Ultralife CorporationULBINASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
23.17%
↑ 575% above average
Average (39q)
3.43%
Historical baseline
Range
High:53.19%
Low:-28.10%
CAGR
-1.2%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 23.17% |
| Q2 2025 | -3.58% |
| Q1 2025 | -0.41% |
| Q4 2024 | 14.90% |
| Q3 2024 | 5.21% |
| Q2 2024 | 13.72% |
| Q1 2024 | -5.18% |
| Q4 2023 | -0.91% |
| Q3 2023 | 5.12% |
| Q2 2023 | -12.50% |
| Q1 2023 | 22.71% |
| Q4 2022 | -12.66% |
| Q3 2022 | 13.40% |
| Q2 2022 | -9.96% |
| Q1 2022 | 15.85% |
| Q4 2021 | -6.96% |
| Q3 2021 | -7.02% |
| Q2 2021 | 12.51% |
| Q1 2021 | 8.50% |
| Q4 2020 | -5.48% |
| Q3 2020 | 25.96% |
| Q2 2020 | -17.64% |
| Q1 2020 | -28.10% |
| Q4 2019 | 6.11% |
| Q3 2019 | 27.85% |
| Q2 2019 | 53.19% |
| Q1 2019 | -5.13% |
| Q4 2018 | -0.64% |
| Q3 2018 | -9.77% |
| Q3 2018 | 10.63% |
| Q2 2018 | 3.97% |
| Q4 2017 | -21.85% |
| Q4 2017 | 14.35% |
| Q3 2017 | 4.13% |
| Q2 2017 | -24.54% |
| Q4 2016 | 11.13% |
| Q3 2016 | -4.77% |
| Q2 2016 | -13.95% |
| Q1 2016 | -1.78% |
| Q4 2015 | 37.75% |